John Bishop Biography and Net Worth

Insider of Ardelyx

John has served as Ardelyx’s Chief Technical Operations Officer since July of 2025, bringing more than 30 years of experience leading technical operations, quality assurance and Chemistry, Manufacturing, and Controls (CMC) regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization.

Prior to Ardelyx, John held the role of Chief Technology Officer at Lyra Therapeutics, where he was responsible for CMC development activities and the build out of a manufacturing facility to support the company as they moved toward commercialization. John also served as Chief Technology Officer at Forma Therapeutics (acquired by Novo Nordisk) from 2017 to 2021. Previously, he held CMC leadership positions Epizyme, Genocea Biosciences, Momenta Pharmaceuticals, Millennium Pharmaceuticals (now Takeda), DuPont Merck Pharmaceutical Company and Alcon Laboratories.

John earned Bachelor degrees in chemistry and German from Tufts University, a doctoral degree in organic chemistry from University of California, Berkeley, and a Master of Business Administration from Northeastern University.

What is John E. Bishop's net worth?: The estimated net worth of John E. Bishop is at least $2.10 million as of February 20th, 2026. Bishop owns 339,151 shares of Ardelyx stock worth more than $2,099,345 as of March 6th. This net worth evaluation does not reflect any other assets that Bishop may own. Learn More about John E. Bishop's net worth.
How do I contact John E. Bishop?: The corporate mailing address for Bishop and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on John E. Bishop's contact information.
Has John E. Bishop been buying or selling shares of Ardelyx?: Over the course of the past ninety days, John E. Bishop has sold $18,597.15 in Ardelyx stock. Most recently, John E. Bishop sold 3,179 shares of the business's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a transaction totalling $18,597.15. Following the completion of the sale, the insider now directly owns 339,151 shares of the company's stock, valued at $1,984,033.35. Learn More on John E. Bishop's trading history.
Who are Ardelyx's active insiders?: Ardelyx's insider roster includes John Bishop (Insider), Robert Blanks (Insider), James Brady (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Susan Hohenleitner (CFO), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Joseph Reilly (Insider), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?: In the last year, Ardelyx insiders bought shares 5 times. They purchased a total of 1,214,710 shares worth more than $5,349,075.66. In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 575,834 shares worth more than $3,146,127.53. The most recent insider tranaction occured on February, 20th when Director David M Mott bought 333,333 shares worth more than $1,946,664.72. Insiders at Ardelyx own 4.8% of the company. Learn More about insider trades at Ardelyx.
Information on this page was last updated on 2/20/2026.

John E. Bishop Insider Trading History at Ardelyx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/20/2026	Sell	3,179	$5.85	$18,597.15	339,151

John E. Bishop Buying and Selling Activity at Ardelyx

Ardelyx Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $6.19

$6.04

$6.27

50 Day Range

MA: $6.87

$5.56

$7.99

2 Week Range

Now: $6.19

$3.21

$8.40

Volume

2,670,193 shs

Average Volume

4,212,689 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61